AGC Biologics Milan Receives Special Award Mention by Confindustria for Research and Innovation
Washingtoner/10237392

SEATTLE ~ AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has been awarded a special mention for Research and Innovation led by Executives Under the Age of 40 by Confindustria. Confindustria is the main association representing manufacturing and service companies in Italy, with a voluntary membership of more than 150,000 companies of all sizes, employing a total of 5,383,286 people.

The AGC Biologics Milan site has a strong team of life science professionals, with 72% of the workforce being under the age of 40. The site's leadership promotes a dynamic and diverse environment to support these team members in their mission to help pharmaceutical companies bring lifesaving treatments to market. 80% at the site hold college degrees, and among those, 16% have achieved a PhD. 61% of leadership positions are held by women.

Francesco De Santis, Vice President of Confindustria for Research and Development noted that "the award is a recognition of companies that have stood out for the quality of innovation" and that "a national commitment is necessary to go with this process and make the national research, development, and innovation system increasingly integrated".

More on Washingtoner

• Boston Industrial Solutions' Natron® DC Series Ink Has Had an Upgrade!
• Colony Ridge Proudly Supports the All Ears! 2025 Sporting Clays Tournament
• Jacob Emrani Nominated for LA Executive Award
• Spokane: Flags Lowered for Former Vice President Richard Cheney
• Kansas City Steak Company Shares the Return of Their Holiday Gift Box

Luca Alberici from AGC Biologics Milan said "this award showcases the work and potential of our business and the young professionals here in Milan that help make our site so successful". He added that "our entire team is driven by innovation in the workplace and delivering the highest level of quality in our work, to ensure patients get the treatments they need".

AGC Biologics acquired its Milan site (formerly MolMed S.p.A.) to add a cell and gene CDMO business to its offerings in July 2020; it has since become the global hub for their cell and gene therapy services. The team at this site has brought multiple products from pre-clinical through commercial phases as well as developed custom plug-and-play systems for vector manufacturing such as AGC's BravoAAV™ and ProntoLVV™ platforms.

The award from Confindustria recognizes AGC Biologics' commitment to research & development as well as their dedication to providing innovative solutions for their clients while also promoting diversity within their workforce.

---

Show All News | Report Violation